Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 12/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12541451 | 0.89 | ELOVL6 (0.47) | ELOVL6CACNA1BNR1I2NPSR1CYP3A4 | |
| SCHEMBL12541453 | 0.89 | ELOVL6 (0.47) | ELOVL6CACNA1BNR1I2NPSR1CYP3A4 | |
| SCHEMBL10476090 | 0.86 | ELOVL6 (0.46) | ELOVL6CACNA1BNR1I2NPSR1CYP3A4 | |
| SCHEMBL1498439 | 0.83 | CACNA1B (0.49) | CACNA1BNR1I2NPSR1CYP3A4POLB | |
| SCHEMBL1498442 | 0.83 | CACNA1B (0.49) | CACNA1BNR1I2NPSR1CYP3A4POLB | |
| SCHEMBL1498403 | 0.82 | POLB (0.43) | ELOVL6CACNA1BNR1I2NPSR1CYP3A4 | |
| SCHEMBL12543113 | 0.79 | GAA (0.43) | ELOVL6CACNA1BNR1I2NPSR1CYP3A4 | |
| SCHEMBL1498496 | 0.79 | HTR6 (0.44) | ELOVL6CACNA1BNR1I2CYP3A4CA1 | |
| SCHEMBL1498584 | 0.79 | CA1 (0.51) | ELOVL6NPSR1CA1CA2MMP1 | |
| SCHEMBL27896516 | 0.79 | CA1 (0.48) | ELOVL6NPSR1CA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
| WO-2011035159-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | ELOVL6 3866/4885CACNA1B 6/4885NR1I2 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.